Recent discussions on X about Ionis Pharmaceuticals (IONS) have been buzzing with excitement following the release of promising Phase 3 trial results for their drug Olezarsen, which showed significant reductions in triglycerides and pancreatitis events. Many users are highlighting the potential blockbuster status of the drug, with some pointing to analyst upgrades and raised price targets as a sign of strong market confidence. The stock's surge to a new high has fueled conversations about its future growth potential.
Additionally, the FDA approval of another drug, Dawnzera, has added to the positive momentum, with several posts on X noting this as a key milestone for the company's pipeline. Investors and observers are actively debating the long-term impact of these developments on the biotech sector as a whole. The tone across these discussions remains largely optimistic, with a focus on the company's innovative strides in RNA-targeted therapies.
Note: This discussion summary was generated from an AI condensation of post data.
Ionis Pharmaceuticals Insider Trading Activity
Ionis Pharmaceuticals insiders have traded $IONS stock on the open market 40 times in the past 6 months. Of those trades, 1 have been purchases and 39 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 6 sales selling 207,546 shares for an estimated $12,457,083.
- PATRICK R. O'NEIL (EVP CLO & General Counsel) has made 0 purchases and 3 sales selling 89,900 shares for an estimated $5,396,843.
- JOSEPH III KLEIN has made 0 purchases and 2 sales selling 56,000 shares for an estimated $3,360,000.
- JOSEPH H WENDER has made 0 purchases and 6 sales selling 56,000 shares for an estimated $3,224,310.
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 3 sales selling 48,909 shares for an estimated $2,741,039.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 3 sales selling 36,728 shares for an estimated $2,057,775.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) has made 0 purchases and 3 sales selling 29,207 shares for an estimated $1,604,121.
- B LYNNE PARSHALL has made 0 purchases and 4 sales selling 25,000 shares for an estimated $1,227,943.
- JOSEPH LOSCALZO sold 16,000 shares for an estimated $962,371
- RICHARD S GEARY (EVP, Chief Development Officer) has made 0 purchases and 2 sales selling 20,000 shares for an estimated $932,264.
- ERIC SWAYZE (EVP Research) has made 0 purchases and 2 sales selling 11,130 shares for an estimated $552,861.
- MICHAEL R HAYDEN purchased 15,000 shares for an estimated $477,900
- SHANNON L. DEVERS (EVP, Chief Human Resources Ofc) sold 3,162 shares for an estimated $192,942
- KYLE JENNE (EVP, Chf GL Pdt Str Ofcr) sold 3,016 shares for an estimated $85,533
- ALLENE M. DIAZ sold 1,427 shares for an estimated $60,687
- BRIAN BIRCHLER (EVP, Corp and Development Ops) sold 680 shares for an estimated $19,291
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Ionis Pharmaceuticals Hedge Fund Activity
We have seen 200 institutional investors add shares of Ionis Pharmaceuticals stock to their portfolio, and 208 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 2,724,400 shares (+253.3%) to their portfolio in Q2 2025, for an estimated $107,641,044
- ORBIMED ADVISORS LLC removed 2,540,136 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $100,360,773
- WELLINGTON MANAGEMENT GROUP LLP removed 2,070,645 shares (-24.6%) from their portfolio in Q2 2025, for an estimated $81,811,183
- MILLENNIUM MANAGEMENT LLC added 2,014,157 shares (+317.0%) to their portfolio in Q2 2025, for an estimated $79,579,343
- CITADEL ADVISORS LLC removed 1,985,081 shares (-57.0%) from their portfolio in Q2 2025, for an estimated $78,430,550
- CLEARBRIDGE INVESTMENTS, LLC removed 1,618,220 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $48,821,697
- NORGES BANK removed 1,264,508 shares (-73.7%) from their portfolio in Q2 2025, for an estimated $49,960,711
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Ionis Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 9 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 09/03/2025
- Goldman Sachs issued a "Sell" rating on 09/03/2025
- Citigroup issued a "Buy" rating on 09/03/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/02/2025
- Jefferies issued a "Buy" rating on 09/02/2025
- Needham issued a "Buy" rating on 09/02/2025
- Raymond James issued a "Strong Buy" rating on 07/31/2025
To track analyst ratings and price targets for Ionis Pharmaceuticals, check out Quiver Quantitative's $IONS forecast page.
Ionis Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 17 analysts offer price targets for $IONS in the last 6 months, with a median target of $65.0.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $80.0 on 09/04/2025
- Gena Wang from Barclays set a target price of $78.0 on 09/03/2025
- David Lebowitz from Citigroup set a target price of $84.0 on 09/03/2025
- Kostas Biliouris from BMO Capital set a target price of $70.0 on 09/03/2025
- Salveen Richter from Goldman Sachs set a target price of $45.0 on 09/03/2025
- Joseph Stringer from Needham set a target price of $70.0 on 09/02/2025
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $95.0 on 09/02/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
